Epsilon Carbon Launches Terrablack, a High-Performing and Environment Friendly Recovered Carbon Black for the Tire and Non-Tire Industries
Epsilon Carbon, a global leader in the carbon black industry, announces the launch of Terrablack, a product line that aims to shape the carbon black sector with sustainability at its core. The unveiling took place in the presence of Mr. Sajjan Jindal, Chairman and MD – JSW Group, Mr. Vikram Handa, Managing Director - Epsilon Carbon, Mr. Gaurav Mathur, CEO and Mr. Desh Deepak Misra, President - Carbon Black business at the Bharat Mobility Show’s India International Tire Exhibition, New Delhi.
Terrablack is designed to address the growing demand for sustainable carbon black. Using recovered carbon black (rCB) and Tire-derived oil (TDO), this product line is formulated after 24 months of in-depth testing and collaboration to shape the future of carbon black production. It offers high-performance, eco-friendly solutions that meet the needs of both Tire and non-Tire industries.
The Terrablack portfolio includes Terrablack 3310, engineered for heavy-duty applications like Tire treads, offering superior wear resistance and durability. Whereas Terrablack 6615, is for flexibility and resilience, ideal for Tire sidewalls, hoses, belts, and sealing systems. Both products are formulated to compliment traditional virgin carbon black and Terrablack lowers the Global Warming Potentialby 40-50% as the case may be, supporting global environmental goals and aiding compliance with global tire recycling standards.
Mr. Vikram Handa, Managing Director of Epsilon Carbon, said, “Terrablack is not just a product; it is a promise to innovate, protect the planet, and drive industries toward a greener future. We believe that innovation, performance and sustainability should go hand in hand, and Terrablack is a testament to that belief and a step in our mission to redefine the carbon black industry and pave the way for a more sustainable tomorrow.”
Epsilon Carbon is advancing its sustainability commitment with building a fully integrated Tire recycling plant in Karnataka, to be operational by FY26. This facility will recycle 30,000 tons of Tires annually, generating 9,500 tons of rCB and 12,000 tons of TDO. This initiative reinforces Epsilon Carbon’s commitment to turning the concept of a circular economy into a practical reality.
About Epsilon Carbon Pvt. Ltd: Epsilon Carbon, a global leader in manufacturing sustainable specialty carbon and carbon black products, catering to diverse industries with 100% backward integrated operations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250120871273/en/
Contacts
Media Contact:
Sandeep: +91 7506148725 I Sandeep.kumar@epsiloncarbon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom